Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

551 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of the association between predictive factors and the development of immune-related adverse events and prognostic factors for chemoimmunotherapy in patients with non-small cell lung cancer: A multicenter retrospective study.
Ozawa R, Sonehara K, Hachiya T, Nozawa S, Agatsuma T, Yamamoto H, Kato A, Matsuo A, Hirabayashi T, Araki T, Komatsu M, Tateishi K, Hanaoka M. Ozawa R, et al. Among authors: hanaoka m. Cancer Med. 2024 Aug;13(15):e70080. doi: 10.1002/cam4.70080. Cancer Med. 2024. PMID: 39096117 Free PMC article.
C-PLAN index as a prognostic factor for patients with previously untreated advanced non-small cell lung cancer who received combination immunotherapy: A multicenter retrospective study.
Sonehara K, Ozawa R, Hama M, Nozawa S, Agatsuma T, Nishie K, Kato A, Matsuo A, Araki T, Komatsu M, Tateishi K, Hanaoka M. Sonehara K, et al. Among authors: hanaoka m. Thorac Cancer. 2023 Feb;14(6):636-642. doi: 10.1111/1759-7714.14798. Epub 2023 Jan 12. Thorac Cancer. 2023. PMID: 36635979 Free PMC article.
Predictive Factors Associated with Long-Term Response to Combination Immunotherapy in Patients with Untreated Advanced Non-Small-Cell Lung Cancer: A Multicenter Retrospective Study.
Sonehara K, Ozawa R, Hama M, Nozawa S, Agatsuma T, Nishie K, Kato A, Matsuo A, Araki T, Komatsu M, Tateishi K, Hanaoka M. Sonehara K, et al. Among authors: hanaoka m. Oncology. 2023;101(7):425-434. doi: 10.1159/000531324. Epub 2023 Jul 7. Oncology. 2023. PMID: 37423211 Free article.
Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study).
Araki T, Kanda S, Komatsu M, Sonehara K, Tateishi K, Takada M, Kato A, Yamamoto M, Nishie K, Hama M, Agatsuma T, Kakizaki Y, Yoshiike F, Matsuo A, Chiaki T, Samizo K, Takagi Y, Yamaura M, Hanaoka M, Koizumi T. Araki T, et al. Among authors: hanaoka m. Transl Lung Cancer Res. 2023 Jun 30;12(6):1320-1327. doi: 10.21037/tlcr-23-12. Epub 2023 Jun 15. Transl Lung Cancer Res. 2023. PMID: 37425417 Free PMC article.
EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.
Araki T, Kanda S, Obara M, Agatsuma T, Kakizaki Y, Hama M, Yamamoto H, Takada M, Yamamoto M, Matsuo A, Kondo D, Komatsu M, Sonehara K, Tateishi K, Hanaoka M, Koizumi T. Araki T, et al. Among authors: hanaoka m. Respir Investig. 2024 Mar;62(2):262-268. doi: 10.1016/j.resinv.2024.01.002. Epub 2024 Jan 20. Respir Investig. 2024. PMID: 38245931 Free article.
551 results